Drug Trial Radar · NCT04630353
A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
10
Actual
Start
Jul 21, 2021
Primary completion
Nov 28, 2023
Study completion Nov 28, 2023
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Hookipa Biotech GmbH
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
Conditions
- HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
HB-201 IVDrug
HB-201 given IV, one (1) time, on day 1.
HB-201 IVDrug
HB-201 given IV, one (1) time, 7 to 14 days prior to definitive chemoradiation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immune response profiles in subjects with HPV 16+ Head and Neck and cervical cancer.Time frame: Approximately 6-8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.